Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study

被引:83
作者
Haro, JM
Edgell, ET
Novick, D
Alonso, J
Kennedy, L
Jones, PB
Ratcliffe, M
Breier, A
机构
[1] San Joan Deu Serv Salut Mental, Res & Dev Unit, St Boi De Llobregat 08030, Barcelona, Spain
[2] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
[3] Eli Lilly & Co Ltd, European Hlth Outcomes Res, Windlesham, Surrey, England
[4] IMAA, IMIM, Barcelona, Spain
[5] Univ Cambridge, Addenbrookes Hosp, Cambridge CB2 2QQ, England
关键词
antipsychotic agents; treatment outcome; schizophrenia; olanzapine; risperidone; quetiapine; amisulpride; clozapine;
D O I
10.1111/j.1600-0447.2004.00450.x
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To present the 6-month outcomes associated with antipsychotic treatment of patients participating in the Schizophrenia Outpatient Health Outcomes (SOHO) study. Method: SOHO is a 3-year, prospective, observational study of the health outcomes associated with antipsychotic treatment in 10 European countries. The study included over 10 000 out-patients who were initiating or changing their antipsychotic medication. Results: Clinical Global Impression (CGI)-severity and quality of life (QOL) scores improved in all treatment cohorts. There was a higher response in the CGI-overall symptoms and in the CGI-schizophrenia positive, negative, cognitive and depressive symptom scales in the olanzapine (Olz) and clozapine (Cloz) cohorts compared with other treatment cohorts. Changes were associated with an improvement in QOL. Conclusion: Patients starting Olz and Cloz tend to have better outcomes at 6 months than patients who start other antipsychotics in actual out-patient clinical practice. The results should be interpreted conservatively because of the non-randomized study design.
引用
收藏
页码:220 / 231
页数:12
相关论文
共 53 条
[1]  
A merican Psychiatric Association, 2001, AM J PSYCHIAT, V154, P1
[2]   A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia [J].
Azorin, JM ;
Spiegel, R ;
Remington, G ;
Vanelle, JM ;
Péré, JJ ;
Giguere, M ;
Bourdeix, I .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (08) :1305-1313
[3]  
Balestrieri M, 2000, HUM PSYCHOPHARM CLIN, V15, P499, DOI 10.1002/1099-1077(200010)15:7<499::AID-HUP194>3.0.CO
[4]  
2-3
[5]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[6]   A comparison of observational studies and randomized, controlled trials. [J].
Benson, K ;
Hartz, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1878-1886
[7]   Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients [J].
Bobes, J ;
Gibert, J ;
Ciudad, A ;
Alvarez, E ;
Cañas, F ;
Carrasco, JL ;
Gascón, J ;
Gómez, JC ;
Gutiérrez, M .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2003, 27 (03) :473-481
[8]  
Bobes J, 1999, ACTAS ESP PSIQUIATRI, V27, P229
[9]  
Britton A, 1998, HLTH TECHNOLOGY ASSE, V2, p[i, 1]
[10]   Effectiveness of antipsychotic therapy in a naturalistic setting: A comparison between risperidone, perphenazine, and haloperidol [J].
Coley, KC ;
Carter, CS ;
DaPos, SV ;
Maxwell, R ;
Wilson, JW ;
Branch, RA .
JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (12) :850-856